Viktor Drvota

Biography

 Dr. Viktor Drvota, M.D., Ph.D., has been the Chief Executive Officer of Karolinska Development AB since June 1, 2017. He served as its Deputy Chief Executive Officer since February 2017 and served as its Chief Investment Officer since February 2016 and also served as its Head of Investment. Dr. Drvota served as the Head of Investment Area Life Science and Senior Investment Manager of SEB Venture Capital from 2002 to December 31, 2015. Dr. Drvota was responsible for business development and life science investments at SEB Venture Capital. Prior to joining SEB Venture in 2002, he worked as a Senior Consultant in Interventional Cardiology and as an Associate Professor in Cardiology at the Karolinska Institute since 2002. He serves as a Director at InDex Pharmaceuticals Holding AB (publ). He serves as a Director of Quiatech AB, Sanos A/S and QuiaPEG AB. He serves as a Director of Neoventa Medical AB and Avidicare AB. He serves as a Deputy Board Member at Arexis AB. He has been a Director of Modus Therapeutics AB (formerly Dilaforette AB) since October 2016. He served as a Member of Supervisory Board at Nuevolution AB (publ) from 2003 to February 1, 2016. He served as a Director of Airsonett AB until March 25, 2016. He served as a Director of InDex Pharmaceuticals AB since 2003. He served as a Director of SciBase Holding AB from 2005 to February 1, 2016 and SBL Vaccin AB. He served as a Deputy Board Member of Neoventa Medical AB. He has published 29 articles in peer reviewed international scientific journals. Dr. Drvota has He has over 15 years' life science investment experience and over 13 years of Venture Capital experience with several investments, significant fundraisings, IPOs and exits. He also has experience from preclinical as well as clinical research in drug development and medical devices both in academia and pharmaceutical industry. He holds a Ph.D. and an M.D.  

Research Interest

 Bussiness Developement